Top Stories

Lupin gets USFDA nod for Tiotropium Dry Powder Inhaler

Jun 23, 2023

By: BlinkX Research Team

Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tiotropium Bromide Inhalation Powder.

The pharma company said in the filing that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, a generic equivalent of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc.

This product will be manufactured at Lupin’s Pithampur facility in India.

Tiotropium Bromide Inhalation Powder (Spiriva® HandiHaler®) had estimated annual sales of USD 1,264 million in the U.S. (IQVIA MAT Mar 2023).

“We are delighted to receive the final approval for generic Spiriva HandiHaler from the U.S. FDA. This builds on our commitment to serving unmet needs for our patients across the world. This is the first generic approval for Spiriva HandiHaler in the U.S., and is also the first DPI approval from India for the U.S. This is an important milestone in our journey of building our respiratory franchise globally,” said Vinita Gupta, CEO, Lupin.

Source: Media reports